John Prince, MD
Pulmonary Disease · Knoxville, TNNPI 1861501991
Payments from drug & device makers
Across 630 payments — averaging $186.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$80K
- Boehringer Ingelheim$18K
- Regeneron Healthcare Solutions, Inc.$11K
- GSK$2K
- Insmed, Inc.$2K
- Amgen$1K
- plus $4K from 31 others
What the payments were for
- Consulting fees$2,8082%
- Speaking & faculty fees$95,51381%
- Travel & lodging$2,1882%
- Food & beverage$16,51914%
- Education$4250%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 200 | $79,789 |
| Boehringer Ingelheim | 61 | $18,436 |
| Regeneron Healthcare Solutions, Inc. | 28 | $11,223 |
| GSK | 108 | $1,761 |
| Insmed, Inc. | 59 | $1,531 |
| Amgen | 30 | $1,054 |
| Grifols USA, LLC | 21 | $406 |
| Actelion Pharmaceuticals US, Inc. | 9 | $361 |
| Sanofi | 16 | $343 |
| Electromed, Inc. | 7 | $295 |
| Baxter Healthcare | 9 | $226 |
| Genentech USA, Inc. | 10 | $193 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $174 |
| Mylan Specialty L.p. | 7 | $151 |
| Philips North America LLC | 8 | $130 |
| Pfizer | 4 | $122 |
| United Therapeutics Corporation | 5 | $118 |
| Galvanize Therapeutics, Inc | 1 | $116 |
| Johnson & Johnson | 1 | $114 |
| Sunovion Pharmaceuticals Inc. | 5 | $102 |
| Sanofi-aventis U.S. LLC | 1 | $95 |
| Inogen, Inc. | 4 | $82 |
| ANI Pharmaceuticals, Inc. | 3 | $76 |
| Merck | 3 | $72 |
| La Jolla Pharmaceutical Company | 2 | $64 |
| Advanced Respiratory, Inc | 4 | $62 |
| Verona Pharma, Inc. | 3 | $61 |
| Pulmonx Corporation | 2 | $51 |
| Viatris Specialty LLC | 2 | $44 |
| Mallinckrodt Hospital Products Inc. | 2 | $41 |
| Phadia US Inc. | 2 | $34 |
| Gilead | 2 | $32 |
| Portola Pharmaceuticals, LLC | 1 | $21 |
| Novartis | 1 | $19 |
| Mallinckrodt Enterprises LLC | 1 | $18 |
| Shire North American Group Inc | 1 | $18 |
| Harmony Biosciences LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$117,452 in reported general payments places this provider in the 90th percentile of 339 pulmonary disease providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 287 | $240,475 |
| OfevNintedanib Esylate | 11 | $142,861 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 151 | $119,685 |
| Breo ElliptaFluticasone/Vilanterol | 118 | $57,797 |
| SymbicortBudesonide/Formoterol Fumarate | 86 | $26,470 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 42 | $23,017 |
| Spiriva RespimatTiotropium Bromide | 12 | $16,596 |
| EliquisApixaban | 22 | $14,680 |
| Arnuity ElliptaFluticasone Furoate | 34 | $7,027 |
| Incruse ElliptaUmeclidinium Bromide | 20 | $6,849 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 35 | $5,051 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 30 | $4,089 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 112 | $3,356 |
| Wixela InhubFluticasone Propion/Salmeterol | 12 | $1,656 |
| BreynaBudesonide/Formoterol Fumarate | 12 | $1,386 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta, Incruse Ellipta | $1,761 | $312,149459 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $18,436 | $182,47465 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $79,789 | $146,154237 claims |
| PfizerEliquis | $122 | $14,68022 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 339 pulmonary disease providers in Tennessee.
Other pulmonary disease in Knoxville
- John SwisherKnoxville$2.3M
- Eric WeaverKnoxville$492K
- Rajiv DhandKnoxville$426K
- John CallisonKnoxville$324K
- Isaac BineyKnoxville$73K
- Varun ShahKnoxville$64K
- Benjamin BevillKnoxville$31K
- Bashar BargotyKnoxville$28K
- Zulma SwankKnoxville$24K
- Shannon ByrdKnoxville$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.